About me
I am a researcher at the Institute of Environmental Medicine at Karolinska Institutet with a background in genetics, cancer and toxicology. In recent years, my main focus has turned towards development of Adverse Outcome Pathways (AOPs) and New Approach Methodologies (NAMs), as well as their application in risk assessment and in safe and sustainable development of new technologies. Coupled to this focus, I also have a broad interest making data Findable, Accessible, Interoperable and Reusable (FAIR). In addition to research, I currently function as coordinator within the Swedish platform for Nanosafety, SweNanoSafe, where I focus on communication, education and sustainability (e.g. Safe and Sustainable by Design) aspects within nanosafety.
Ongoing projects and involvements:
Toward risk assessment without animals: Development of Adverse Outcome Pathways for lung cancer
PARC - European Partnership for the Assessment of Risks from Chemicals
Gov4Nano - Implementation of Risk Governance: meeting the needs of nanotechnology
HARMLESS - Advanced high aspect ratio multicomponent materials: towards comprehensive intelligent testing and safe by design strategies
Selected previous projects and involvements:
eNanoMapper - A Database and Ontology Framework for Nanomaterials Design and Safety Assessment
NANoREG - A common European approach to the regulatory testing of nanomaterials
NANOSOLUTIONS - Biological Foundation for the Safety Classification of Engineered Nanomaterials (ENM): Systems Biology Approaches to Understand Interactions of ENM with Living Organisms and the Environment
NanoReg2 - Development and implementation of Grouping and Safe-by-Design approaches within regulatory frameworks
caLIBRAte - Performance testing, calibration and implementation of a next generation system-of-systems Risk Governance Framework for nanomaterials
PATROLS – Physiologically Anchored Tools for Realistic nanOmateriaL hazard aSsessment
NanoSolveIT – Innovative Nanoinformatics models and tools: towards a Solid, verified and Integrated Approach to Predictive (eco)Toxicology
miRNAno - Toxicogenomic studies on engineered carbon nanomaterials
Research description
Selected publications:
Grafström R, Haase A, Kohonen P, Jeliazkova N, Nymark P. Reply to: Prospects and challenges for FAIR toxicogenomics data. Nat Nanotechnol. 2021 Dec 23. doi: 10.1038/s41565-021-01050-8. Online ahead of print.
Lynch I, Nymark P, Doganis P, Gulumian M, Yoon TH, Martinez DST, Afantitis A. Methods, models, mechanisms and metadata: Introducing the Nanotoxicology collection at F1000Research. F1000Res. 2021 Nov 24;10:1196. doi: 10.12688/f1000research.75113.1. eCollection 2021.
Bossa C, Andreoli C, Bakker M, Barone F, De Angelis I, Jeliazkova N, Nymark P, Battistelli CL. FAIRification of nanosafety data to improve applicability of (Q)SAR approaches: A case study on in vitro Comet assay genotoxicity data. Comput Toxicol. 2021 Nov;20:100190. doi: 10.1016/j.comtox.2021.100190.
Jeliazkova N, Apostolova MD, Andreoli C, Barone F, Barrick A, Battistelli C, Bossa C, Botea-Petcu A, Châtel A, De Angelis I, Dusinska M, El Yamani N, Gheorghe D, Giusti A, Gómez-Fernández P, Grafström R, Gromelski M, Jacobsen NR, Jeliazkov V, Jensen KA, Kochev N, Kohonen P, Manier N, Mariussen E, Mech A, Navas JM, Paskaleva V, Precupas A, Puzyn T, Rasmussen K, Ritchie P, Llopis IR, Rundén-Pran E, Sandu R, Shandilya N, Tanasescu S, Haase A, Nymark P. Towards FAIR nanosafety data. Nat Nanotechnol. 2021 May 20. doi: 10.1038/s41565-021-00911-6.
Nymark P, Karlsson HL, Halappanavar S, Vogel U. Adverse Outcome Pathway development for assessment of lung carcinogenicity by nanoparticles. Frontiers in Toxicology, 29 April 2021. doi: 10.3389/ftox.2021.653386
Nymark P, Sachana M, Batista-Leite S, Sund J, Krebs C.E., Sullivan K, Edwards S, Viviani L, Willett K, Landesmann B, Wittwehr C. Systematic Organization of COVID-19 Data Supported by the Adverse Outcome Pathway Framework. Frontiers in Public Health, 19 May 2021, doi: 10.3389/fpubh.2021.638605
Halappanavar S, van den Brule S, Nymark P, Gaté L, Seidel C, Valentino S, Zhernovkov V, Høgh Danielsen P, De Vizcaya A, Wolff H, Stöger T, Boyadziev A, Poulsen SS, Sørli JB, Vogel U. Adverse outcome pathways as a tool for the design of testing strategies to support the safety assessment of emerging advanced materials at the nanoscale. Part Fibre Toxicol. 2020 May 25;17(1):16. doi: 10.1186/s12989-020-00344-4.
Nymark P, Bakker M, Dekkers S, Franken R, Fransman W, García-Bilbao A, Greco D, Gulumian M, Hadrup N, Halappanavar S, Hongisto V, Hougaard KS, Jensen KA, Kohonen P, Koivisto AJ, Dal Maso M, Oosterwijk T, Poikkimäki M, Rodriguez-Llopis I, Stierum R, Sørli JB, Grafström R. Toward Rigorous Materials Production: New Approach Methodologies Have Extensive Potential to Improve Current Safety Assessment Practices. Small. 2020 Feb;16(6):e1904749. doi: 10.1002/smll.201904749. Epub 2020 Jan 8.
Soeteman-Hernandez LG, Apostolova MD, Bekker C, Dekkers S, Grafström RC, Groenewold M, Handzhiyski Y, Herbeck-Engel P, Hoehener K, Karagkiozaki V, Kelly S, Kraegeloh A, Logothetidis S, Micheletti C, Nymark P, Oomen A, Oosterwijk T, Rodríguez-LLopis I, Sabella S, Sanchez Jiménez A, Sips A, Suarez-Merino B, Tavernaro I, van Engelen J, Wijnhoven SWP, Noorlander CW. Safe innovation approach: Towards an agile system for dealing with innovations. Materials Today Communications, Volume 20, 2019, 100548, ISSN 2352-4928, doi: 10.1016/j.mtcomm.2019
Giusti A, Atluri R, Tsekovska R, Gajewicz A, Apostolova MD, Battistelli CL, Bleeker EAJ, Bossa C, Bouillard j, Dusinska M, Gómez-Fernández P, Grafström R, Gromelski M, Handzhiyski Y, Jacobsen NR, Jantunen P, Jensen KA, Mech A, Navas JM, Nymark P, Oomen AG, Puzyn T, Rasmussen K, Riebeling C, Rodriguez-Llopis I, Sabella S, Riego Sintes J, Suarez-Merino B, Tanasescu S, Wallin H, Haase A. Nanomaterial grouping: Existing approaches and future recommendations. NanoImpact, Volume 16, 2019, 100182, ISSN 2452-0748, doi: 10.1016/j.impact.2019.100182
Nymark P, Kohonen P, Hongisto V, Grafström RC. Toxic and Genomic Influences of Inhaled Nanomaterials as a Basis for Predicting Adverse Outcome. Ann Am Thorac Soc. 2018 Apr;15(Suppl 2):S91-S97. doi: 10.1513/AnnalsATS.201706-478MG.
Nymark P, Rieswijk L, Ehrhart F, Jeliazkova N, Tsiliki G, Sarimveis H, Evelo CT, Hongisto V, Kohonen P, Willighagen E, Grafström RC. A Data Fusion Pipeline for Generating and Enriching Adverse Outcome Pathway Descriptions. Toxicol Sci. 2018 Mar 1;162(1):264-275. doi: 10.1093/toxsci/kfx252.
Nymark P, Wijshoff P, Cavill R, van Herwijnen M, Coonen ML, Claessen S, Catalán J, Norppa H, Kleinjans JC, Briedé JJ. Extensive temporal transcriptome and microRNA analyses identify molecular mechanisms underlying mitochondrial dysfunction induced by multi-walled carbon nanotubes in human lung cells. Nanotoxicology, 2015. 9(5): p. 624-635. doi: 10.3109/17435390.2015.1017022
Nymark P, Guled M, Borze I, Faisal A, Lahti L, Salmenkivi K, Kettunen E, Anttila S, Knuutila S. Integrative Analysis of microRNA, mRNA and aCGH Data Reveals Asbestos-Related Changes in Non-Small Cell Lung Cancer. Genes, Chromosom. Cancer, 2011. 50(8):585-97. doi: 10.1002/gcc.20880
Nymark P, Wikman H, Hienonen-Kempas T, Anttila S. Molecular and genetic changes in asbestos-related lung cancer. Cancer Lett. 2008. 265(1):1-15. Doi: 10.1016/j.canlet.2008.02.043